Avia Logo

Compare Products


Jump to:
Categories
Solutions
Description
Compatibility Level
Clients
Use cases
EHR integrations
Client types
Differentiators
Keywords
Media
Company details
Jump to:
Categories
Solutions
Description
Compatibility Level
Clients
Use cases
EHR integrations
Client types
Differentiators
Keywords
Media
Company details

Categories

Solutions

Description

Product Description:
Using our Geneticure platform, our team of scientists has developed a COVID19 solution, potentially creating an important short-term advance until a vaccine. One of the most common co-morbidities in patients who develop severe illness is hypertension, an area where we have profound expertise in the genetics of the disease and treatment response. Like in hypertension treatment, we have identified genetic influences within the renin-angiotensin-aldosterone system (RAAS) that we believe will be beneficial in predicting the severity of, and guiding treatment for, COVID19 patients. Many companies and academics are tackling this from various angles leaning on their expertise to help save lives and preserve resources, we hope to do the same. Here’s how: COVID-19, like other coronaviruses, bind to and utilize, angiotensin-converting enzyme 2 (ACE2) as a host receptor in order to infect cells resulting in respiratory illness in humans. This is the lock-and-key allowing entry into the cells. As we all have learned, some can carry and transmit the virus without any symptoms, some with mild symptoms, and some with severe enough complications resulting in death. Hypertension can cause changes in the RAAS (as an important counter-regulatory pathway to balance increases in blood pressure) and common blood pressure medications have shown to modulate ACE2 levels in small trials. Several other clinical comorbidities and demographic variables including diabetes, age, and sex have been shown to cause changes in the RAAS in animal models: these are all associated with differences in COVID-19 presentation. Using the data that are available from these patients with varying levels of severity, it is clear that differences in endogenous ACE2 levels may alter the risk of disease transmission along with the degree of severity of disease progression. Not all hypertensives, diabetics, or men develop COVID-19, and many without these factors ultimately develop COVID-19 at varying degrees of severity, suggesting genetics may be one of many factors that is important. Interestingly, there are important potential differences in the importance of ACE2 pre-vs. post-infection. With high ACE2 levels likely being protective for the heart and lungs post-infection. Given this complex relationship: further study is certainly warranted. With our cheek-swab test, we can identify patients who likely have low vs. high ACE2 levels, based on genetic variants important in the RAAS, to triage their risk for disease progression. We are beginning clinical research trials on this. We can also utilize this genetic information to suggest common medication adjustments that can be utilized to reduce ACE2 concentrations, hopefully improving outcomes and saving lives.
About Geneticure:
Geneticure’s tests predict response to drug and device therapy for chronic and dangerous diseases. This shortens and optimizes the path to wellness. In hypertension, Geneticure demonstrated the ability to control 97% of patients within 6 months, with 36% lower blood pressure vs. standard of care: saving $1300 per patient per year - as evidenced in 3 clinical studies and 5 peer-reviewed scientific papers.
Product Description:
Continuous Precision Medicine, Inc. provides personalized solutions for controlled medication management. Led by Steven, a medically trained inventor and successful entrepreneur with over a decade of healthcare experience, the company is at the forefro...
About Continuous Precision Medicine (CPM):
Continuous Precision Medicine, Inc. provides personalized solutions for controlled medication management. Led by Steven, a medically trained inventor and successful entrepreneur with over a decade of healthcare experience, the company is at the forefro...

Compatibility level

Select which hospital or health system you work at and see a personalized compatibility level.

Clients

Select which hospital or health system you work at and see the client list

Use Cases

Description:

None provided

Pediatric use cases:

None provided

Users:

None provided

Description:

None provided

Pediatric use cases:

None provided

Users:

None provided

EHR Integrations

Integrations:

None provided

EMR Integration & Relevant Hardware:

None provided

EMRs Supported:

None provided

Hardware Compatibility:

None provided

Integrations:

None provided

EMR Integration & Relevant Hardware:

None provided

EMRs Supported:

None provided

Hardware Compatibility:

None provided

Client Types

None provided
None provided

Differentiators

Differentiators vs EHR Functionality:

None provided

Differentiators vs Competitors:

None provided

Differentiators vs EHR Functionality:

None provided

Differentiators vs Competitors:

None provided

Keywords

Images

No images provided

No images provided

Videos

No videos provided

No videos provided

Downloads

No content provided

No content provided

Alternatives

Company Details

Founded in 2014

team illustration
Share your product comparison with your collegues.

Need help narrowing down products?

Add more criteria to see your compatibility level for every vendor. It only takes a few minutes, just create a free account to get started.
back to top